Concept Medical
Concept Medical has initiated the “MAGICAL-ISR” IDE clinical study in the US, utilizing the MagicTouch Sirolimus drug-coated balloon (DCB) for in-stent restenosis (ISR) management.
The study, granted ‘Breakthrough Device’ designation and FDA Investigational Device Exemption (IDE) approval, aims to evaluate the safety and efficacy of MagicTouch in treating ISR. Led by renowned physicians, the study focuses on patients avoiding Target Lesion Failure (TLF) within one year post-procedure.
MagicTouch offers controlled Sirolimus release without permanent scaffold implantation, marking a significant advancement in coronary intervention. This development reflects Concept Medical’s commitment to innovation and patient care.
Dr Manish Doshi, Founder & Managing Director of Concept Medical says, “The MagicTouch technology has been embraced globally, and its entry into the US market through this study, represents a critical step towards addressing the unmet needs in ISR treatment. Our commitment to innovation and patient safety is unwavering, and we anticipate this study will significantly impact how ISR is treated worldwide.”
Read More Business News
CIMB Islamic contributes RM500,000 to UPSI Edu-Forest project supporting biodiversity conservation, research, education and Orang…
− Sandoz Malaysia has partnered with Sunway Medical Centre to expand patient access to biosimilarsthrough education and…
Raw IoT data is often just noise. AI turns this data into "actionable wisdom," explains.
Scoot has ordered 11 Airbus A320neo aircraft to enhance its fleet, supporting growth and improving…
The FBM KLCI shows positive movement, with expectations to range between 1,755-1,765, driven by anticipated…
CIMB Group appointed Mak Joon Nien as CEO of Growth Markets and CEO of CIMB…
This website uses cookies.
